# US 2015/0105346 A1 · Dextran-based polymer tissue adhesive for medical use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105346 A1
- Document ID: US20150105346A1
- Status: Published application
- Kind: A1
- Application number: 14/465,037
- Filed: 2014-08-21
- Published: 2015-04-16
- Earliest claimed: 2007-11-14
- Assignees: Actamax Surgical Materials, LLC
- Applicants: Actamax Surgical Material, LLC
- Inventors: Helen S.M Lu
- Web page: https://patentgrep.com/patent/US20150105346A1

## CPC

- A61L 24/08: Polysaccharides {(A61L24/043 takes precedence)}
- A61L 24/0031: {Hydrogels or hydrocolloids}
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum.

## Claims

### Claim 1

A method for applying a coating to an anatomical site on tissue of a living organism comprising:
applying to the site
a) at least one dextran that has been derivatized to provide at least one aminodextran that contains primary amine groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one aminodextran having an amine substitution level of about 5% to about 65%; followed by
b) at least one dextran that has been oxidized to provide at least one oxidized dextran containing aldehyde groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one oxidized dextran having an equivalent weight per aldehyde group of about 65 to about 1500 Daltons;
or applying (b) followed by (a) and mixing (a) and (b) on the site;
or premixing (a) and (b) and applying the resulting mixture to the site.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the aminodextran is a first aqueous solution or dispersion and the oxidized dextran a second aqueous solution or dispersion.

### Claim 3 (depends on 2)

The method according to claim 2 wherein the first aqueous solution or dispersion contains the aminodextran at a concentration of about 5% to about 70% by weight relative to the total weight of the solution or dispersion.

### Claim 4 (depends on 2)

The method according to claim 2 wherein the second aqueous solution or dispersion contains the oxidized dextran at a concentration of about 5% to about 50% by weight relative to the total weight of the solution or dispersion.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the aminodextran and the oxidized dextran are finely divided powders.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the equivalent weight per aldehyde group of the oxidized dextran is about 90 to about 1500 Daltons.

### Claim 7

A method for bonding at least two anatomical sites together comprising:
applying to at least one of the at least two anatomical sites:
a) at least one dextran that has been derivatized to provide at least one aminodextran that contains primary amine groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one aminodextran having an amine substitution level of about 5% to about 65%; followed by
b) at least one dextran that has been oxidized to provide at least one oxidized dextran containing aldehyde groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one oxidized dextran having an equivalent weight per aldehyde group of about 65 to about 1500 Daltons; or alternatively, applying (b) followed by (a) and mixing (a) and (b) on the at least one site, or alternatively, premixing (a) and (b) and applying the resulting mixture to the at least one site; and contacting the at least two anatomical sites together.

### Claim 8 (depends on 7)

The method according to claim 7 wherein the aminodextran is a first aqueous solution or dispersion and the oxidized dextran a second aqueous solution or dispersion.

### Claim 9 (depends on 8)

The method according to claim 8 wherein the first aqueous solution or dispersion contains the aminodextran at a concentration of about 5% to about 70% by weight relative to the total weight of the solution or dispersion.

### Claim 10 (depends on 8)

The method according to claim 8 wherein the second aqueous solution or dispersion contains the oxidized dextran at a concentration of about 5% to about 50% by weight relative to the total weight of the solution or dispersion.

### Claim 11 (depends on 7)

The method according to claim 7 wherein the aminodextran and the oxidized dextran are finely divided powders.

### Claim 12 (depends on 7)

The method according to claim 7 wherein the equivalent weight per aldehyde group of the oxidized dextran is about 90 to about 1500 Daltons.
